Usage of Acyclovir for Suppression of HIV-1 and HSV-2 Coinfected Persons in Cameroon
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The study proposed that both clinical and subclinical HSV reactivation is associated with
increased HIV shedding from mucosal surfaces, which may increase the infectiousness of
HIV-1/HSV-2 coinfected persons. To test this hypothesis, we will control HSV reactivation
with acyclovir, a safe medication that is proven to reduce HSV shedding, and measure HIV
levels in blood, genital, and pharyngeal secretions. The study hypothesizes that acyclovir
will reduce HIV shedding from mucosal surfaces of HIV-1/HSV-2 coinfected individuals.